about
Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysisDiscovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptorsDiscovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorDiscovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with NecroptosisDNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase InhibitorsThe discovery of potent cRaf1 kinase inhibitorsDiscovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.Recent progress on MAP kinase pathway inhibitors.Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice.Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.Herpes simplex virus suppresses necroptosis in human cells.Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium.High throughput screening identifies ATP-competitive inhibitors of the NLRP1 inflammasome.Antioxidant Activity of 3-[N-(Acylhydrazono)ethyl]-4-hydroxy-coumarins.RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and InflammationDiscovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) KinaseElevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell deathIdentification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic CancerRIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerRetraction
P50
Q27636502-57472FA8-0B0B-4ABD-95A3-25C28E9C91ACQ27646947-C3264F04-ACBB-4C35-862E-436BF55807B6Q27651145-4AC2ADDE-742D-485A-8282-FD8852EDE302Q27684187-D356D9E1-619E-4506-BB49-90255E73D62CQ27703989-4C0D5250-30DD-49A4-9A42-E760067D2A91Q28372045-BFF1D013-C36F-4B45-ADED-C2A606D0E3EDQ36267226-A80598EE-0110-411F-866F-F4239DF367B8Q38442446-6821E5C9-8880-4AA6-B616-754E8E7559C3Q40416781-C2AAB6E7-1E95-49A7-B22B-99E26408CBDEQ40555960-324610A8-B8EC-4A33-A1C7-77ACB2BBF957Q41487815-861026D0-844A-4C21-B92D-2682182B67B2Q44794287-DFC932F8-F67E-4014-8A3E-09CD0EDC3056Q45294481-93309270-13AC-4D1F-A71D-F92612090AC4Q47115973-D6DF4FAA-010F-4D7E-9CAF-77BB184C9113Q47133521-CCDA6B4E-5268-4734-B1BF-E921FA208BCEQ47581102-D5263AB3-F9DC-46F2-BDDE-8FB8A5080DD8Q50971166-FB176957-DA82-492F-A681-1C0A031F933CQ51548192-C620A923-79CE-4ECA-BD9F-AF6909F856D9Q64243988-FF73CF7B-4E28-4CD6-B91B-201040DD06ADQ90234955-7E7F6C9A-5DAD-4192-9F5B-718311901AAFQ91410295-403582FE-00FF-4553-A7EB-399A881B3138Q92929436-0497BD41-DE91-4C14-8B2D-7DBBCD4A8D02Q93037082-B38DD537-94F6-4780-BB3E-68B430319A18Q94166914-2D51BE3F-5263-41CC-95D7-EEC7B56EF4D9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philip A Harris
@ast
Philip A Harris
@de
Philip A Harris
@en
Philip A Harris
@es
Philip A Harris
@fr
Philip A Harris
@it
Philip A Harris
@nl
type
label
Philip A Harris
@ast
Philip A Harris
@de
Philip A Harris
@en
Philip A Harris
@es
Philip A Harris
@fr
Philip A Harris
@it
Philip A Harris
@nl
prefLabel
Philip A Harris
@ast
Philip A Harris
@de
Philip A Harris
@en
Philip A Harris
@es
Philip A Harris
@fr
Philip A Harris
@it
Philip A Harris
@nl
P106
P1153
7403636588
P31
P496
0000-0002-5189-3326